Clinical trials to inform new treatments for Alzheimer’s disease face more significant challenges in recruiting participants than most other disease areas. These trials also take longer to complete, cost more and often lack qualified participants from diverse backgrounds.
To tackle the steepest barriers to recruitment, the USC Schaeffer Center and the Keck School of Medicine of USC’s Alzheimer’s Therapeutic Research Institute (ATRI) partnered with Gates Ventures to form an advisory panel with more than 35 experts from across the private and public sectors.
The expert panel convened over the course of a year to identify critical challenges and potential solutions. Among the recommendations: broadening cognitive screening and early detection efforts, changing payment models and developing better tools for primary care providers.
To continue reading this story, click here.